Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Activation of the JNK–ENO1 Axis Promotes Glycolytic Reprogramming and Progression of Retroperitoneal Leiomyosarcoma

ABSTRACT: Retroperitoneal leiomyosarcoma (RPLMS) is a highly aggressive malignancy with limited therapeutic options, and its metabolic underpinnings remain poorly understood. In this study, we identified significant activation of glycolytic pathways in RPLMS through RNA-seq analysis, with enolase 1 (ENO1) markedly upregulated in both tumor tissues and patient-derived cell lines. Functional experiments demonstrated that ENO1 knockdown suppresses proliferation, migration, and glycolytic metabolism in RPLMS cells. Mechanistically, JNK signaling was shown to directly promote ENO1 transcription, thereby driving glycolytic reprogramming. Our findings reveal that the JNK–ENO1 axis plays a critical role in RPLMS progression, suggesting that targeting this pathway may represent a promising therapeutic strategy for this devastating disease.

ORGANISM(S): Mus musculus

PROVIDER: GSE315333 | GEO | 2026/06/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Activation of the JNK–ENO1 Axis Promotes Glycolytic Reprogramming and Progression of Retroperitoneal Leiomyosarcoma

Project description:Activation of the JNK–ENO1 Axis Promotes Glycolytic Reprogramming and Progression of Retroperitoneal Leiomyosarcoma

| PRJNA1395654 | ENA

ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1

Project description:ENO1 (α-Enolase 1) is a key glycolytic enzyme that catalyzes the dehydratation of 2-phosphoglycerate to phosphoenolpyruvate. It also belongs to a member of the RNA degradosome of Escherichia coli and facilitates RNA degradation, but it’s currently unknown whether ENO1 possesses similar function in eukaryotes. To test this possibility,we performed RNA-seq assays expressing NTC or ENO1 shRNA, respectively.

2021-09-10 | GSE153989 | GEO

ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism

Project description:Enolase 1 (ENO1) is a glycolytic enzyme that plays essential roles in various pathological activities including cancer development. However, the mechanisms underlying ENO1-contributed tumorigenesis are not well explained. Here, we uncover that ENO1, as an RNA-binding protein, binds to the cytosine-uracil-guanine-rich elements of YAP1 messenger RNA to promote its translation. ENO1 and YAP1 positively regulate alternative arachidonic acid (AA) metabolism by inverse regulation of PLCB1 and HPGD (15-hydroxyprostaglandin dehydrogenase). The YAP1/PLCB1/HPGD axis-mediated activation of AA metabolism and subsequent accumulation of prostaglandin E2 (PGE2) are responsible for ENO1-mediated cancer progression, which can be retarded by aspirin. Finally, aberrant activation of ENO1/YAP1/PLCB1 and decreased HPGD expression in clinical hepatocellular carcinoma samples indicate a potential correlation between ENO1-regulated AA metabolism and cancer development. These findings underline a new function of ENO1 in regulating AA metabolism and tumorigenesis, suggesting a therapeutic potential for aspirin in patients with liver cancer with aberrant expression of ENO1 or YAP1.

2023-05-19 | GSE183703 | GEO

ENO1 influences ATP pool of cytoplasm and lactate homeostasis by regulating glycolysis to promote tumor stemness and metastasis

Project description:This study demonstrated the role of the glycolytic enzyme alpha-enolase (ENO1) on glycolysis and stemness in gastric cancer (GC). High ENO1 expression was associated with poor prognosis and promoted malignant phenotypes and stem-like characteristics in GC. Mechanistically, ENO1 directly stimulated lactate and ATP production by regulating glycolysis, affecting lactate homeostasis and intracellular ATP pools, and co-regulating the AMPK/mTOR and PI3K/AKT signaling pathways. This ultimately drove GC stemness, epithelial-mesenchymal transition (EMT)-related markers, self-renewal, migration, and invasion.

2025-09-27 | GSE307717 | GEO

PCNA regulates metabolism by stabilizing ENO1 and 6PGD

Project description:The essential roles of PCNA as a scaffold protein in DNA replication and repair are well established, while its more recently discovered cytosolic roles are less explored. Alpha-enolase (ENO1) and 6-phosphogluconate dehydrogenase (6PGD), important proteins in glycolysis and the Pentose Phosphate Pathway (PPP), respectively, both contain PCNA interacting motifs. Here we show reduced binding to PCNA when the PCNA interacting motif APIM in ENO1 is mutated. Mutant cells have lower ENO1 protein levels, have reduced glucose consumption, altered glycolytic metabolite and nucleoside phosphate pools and increased activation of the citric acid cycle (TCA) compared to parental cells. Treatment of a panel of haematological cell lines with a cell penetrating peptide containing APIM (ATX-101), lead to a metabolic shift with reduction in glycolytic metabolite and nucleoside phosphate pools as well reduced levels of ENO1 and 6PGD proteins. These results suggests that PCNA stabilize ENO1 and 6PGD, and that targeting PCNA reduce the glycolysis, PPP and nucleoside phosphate pools via destabilization of these proteins.

2023-03-10 | PXD028314 | Pride

ENO1 couples HDAC1 to regulate histone lactylation and gene transcription

Project description:Histone deacetylases (HDACs) are essential transcriptional regulators that mediate gene expression through the complexes they are involved in. Thus, deciphering the HDAC-associated proteins is key to elucidating the underlying mechanisms. Here we present an efficient tool, termed heterobifunctional molecule-enabled proximity labeling strategy (BimPL), to investigate endogenous HDAC neighboring proteins in living cells. Leveraging BimPL and quantitative proteomics, we enable the robust capture of several known HDAC complexes as well as numerous putative HDAC interactors such as glycolytic enzyme enolase-1 (ENO1). Through biochemical studies and CUT&Tag analysis, we uncovered that nuclear ENO1 interacts with HDAC1, which in turn blunts the activity of HDAC1 via locally generated phosphoenolpyruvate (PEP), thereby mediating histone lysine lactylation (Kla) and gene transcription. Our study offers a versatile tool for systematic exploring endogenous protein complexes, as well as provides insight into the unidentified function of ENO1 in the regulation of histone Kla and liver tumor progression.

2025-05-01 | GSE291520 | GEO

Effects of ENO1 knockdown and LPS+Lactate stimulation on EA.HY926 cells

Project description:Elevated lactate was associated with vascular endothelial cells (ECs) dysfunction in sepsis. However, the underlying mechanisms remain to be defined. In this study, we found that elevated lactate in sepsis promotes lactylation of enolase 1 (ENO1) at K71 site through the action of lactyltransferase P300. The lactylation at ENO1 K71 site reduces the binding of TRIM21(an E3 ubiquitin ligase) mRNA to ENO1 (an RNA-binding protein), resulting in enhanced TRIM21 mRNA stability and expression. Elevated TRIM21 can bind to VE-Cadherin and exert its E3 ubiquitin ligase function, causing the ubiquitination and degradation of VE-Cadherin, which disrupts endothelial adhesions junctions (AJs) and increases endothelial permeability. Targeting lactylation of ENO1 K71 via a specific peptide alleviated endothelial injury and enhanced survival rates among septic mice. These findings suggest that lactyaltion of ENO1 plays a pivotal role in vascular endothelial dysfuncyion during sepsis, while inhibiting lactylation may offer a novel strategy for sepsis treatment.

2026-01-21 | GSE281679 | GEO

FBXL6 promotes bladder cancer progression by stabilizing ENO1 through K63-linked ubiquitination

Project description:Ubiquitin-mediated post-translational modifications play critical roles in tumor progression, yet their regulatory mechanisms in bladder cancer (BLCA) remain incompletely understood. Here, we identified FBXL6, belonging to the F-box protein family, as a potential oncogenic driver in BLCA through integrative bioinformatic analysis of multiple public datasets and validation in clinical specimens. Functional analyses demonstrated that FBXL6 accelerates both the in vitro proliferation and migration of BLCA cells and the in vivo progression of tumors and metastatic spread. Mechanistically, transcriptomic profiling and metabolic analyses suggested that FBXL6 regulates glycolysis, with particular involvement of the glycolytic enzyme ENO1. While ENO1 mRNA remained largely unchanged upon FBXL6 knockdown, Western blot analysis revealed corresponding changes in ENO1 protein levels, indicating post-transcriptional regulation. Co-immunoprecipitation assays confirmed a physical interaction between FBXL6 and ENO1, and domain-mapping analysis revealed that the leucine-rich repeat (LRR) region of FBXL6 mediates ENO1 binding. Moreover, ubiquitination assays demonstrated that FBXL6 enhances K63-linked polyubiquitination of ENO1, leading to its stabilization. Restoration of ENO1 expression partially rescued the suppressed proliferation and migration induced by FBXL6 knockdown, as demonstrated by rescue assays. Overall, our data support a novel model in which FBXL6 facilitates BLCA progression through K63-linked stabilization of ENO1, highlighting its potential value in targeted therapy for bladder cancer.

2026-04-26 | GSE295700 | GEO

ENO1 siRNA knockdown in Human HeLa cells

Project description:HeLa cells were either treated with ENO1 or control siRNAs using the protocol of the RNAiMax reagent (ENO1 pool: SMARTpool ON-TARGETplus L-004034-00-0005 and control pool: ON-TARGETplus non-targeting siRNAs 1-4). Three replicates per condition were produced.

2020-10-27 | E-MTAB-9032 | biostudies-arrayexpress

Spatially-Resolved Multiomic Atlas of Leiomyosarcoma Identifies Two Clinically Relevant Epigenetically-Driven Cell States [scMultiomic]

Project description:Leiomyosarcoma (LMS) is a malignant smooth muscle tumor characterized by substantial clinical and molecular heterogeneity. To investigate the cellular and regulatory landscape of LMS at single-cell resolution, we performed single-nucleus multiome sequencing to jointly profile gene expression (snRNA-seq) and chromatin accessibility (snATAC-seq) in 16 untreated primary leiomyosarcoma tumors arising from retroperitoneal, extremity, and uterine sites. After quality control, 94,439 nuclei were analyzed, revealing diverse tumor and microenvironmental cell populations including macrophages, T cells, and endothelial cells. Malignant cells segregated predominantly into two major transcriptional and epigenetic states: a dedifferentiated mesenchymal-like subtype (MES) and a differentiated smooth muscle cell–like subtype (SMC). Integration of transcriptomic and chromatin accessibility profiles identified distinct regulatory programs underlying these states, including enrichment of NFI transcription factor motifs in MES cells and AP-1 family motifs in SMC cells. These data provide a comprehensive multiomic resource for understanding tumor heterogeneity and regulatory mechanisms in leiomyosarcoma.

2026-04-01 | GSE324206 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data